Navigation Links
Mylan Appoints Anthony Mauro Chief Commercial Officer
Date:2/22/2016

HERTFORDSHIRE, England and PITTSBURGH, Feb. 22, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Anthony (Tony) Mauro to chief commercial officer.

In his new role, which reports to Mylan President Rajiv Malik, Mauro will now be responsible for overseeing global sales excellence and operations of all commercial markets around the world. Until his successor is appointed, Mauro will continue his current role as president of North America.

Mauro has been with Mylan for more than 20 years and has successfully led its largest commercial business – the North American region – for the last four of them. He has served the company in several capacities of increasing responsibility, including president of Mylan Pharmaceuticals Inc., the company's flagship generics division in the U.S.; chief operating officer of Mylan Pharmaceuticals ULC in Canada; vice president of North America Strategic Development; and vice president of North America Sales. Mauro also served as chairman of the board of directors for the U.S. Generic Pharmaceutical Association (GPhA) for two consecutive terms in 2012 and 2013, and prior to that served two consecutive terms as vice chairman of the board for GPhA.

Mylan CEO Heather Bresch commented: "Tony has been instrumental in Mylan's success to date, particularly in his strong leadership of our North American commercial business. During his tenure, Tony has demonstrated his ability to relentlessly drive innovation, provide our customers with exceptional and reliable service, and has maximized opportunities while overcoming challenges and consistently delivered strong financial performance. In Tony's new leadership role, Mylan will be better positioned for Tony to continue to drive sales excellence throughout all of Mylan's global commercial markets."

Mylan President Rajiv Malik added: "Tony has demonstrated a proven track record of driving success in our North America commercial operations and enhancing our relationships with customers, particularly as they continue to expand globally. As a result, Tony has certainly earned the opportunity to continue his success with Mylan and now by driving global sales excellence throughout our global commercial operations. I look forward to his continued strong partnership and strategic input as we continue to grow and strengthen our business in existing markets and expand our commercial footprint in new regions."

Mauro said: "I have had the privilege of being part of Mylan for more than 20 years and contributing to the company's evolution from a leading generics pharmaceutical company in the U.S. to a leading global pharmaceutical company. Mylan's future has never been brighter, and I am proud to have been recognized and ready to step up to be a part of Mylan's senior organizational leadership team as we continue our exciting growth trajectory, while delivering on our mission to set new standards in healthcare."

This press release includes statements that constitute "forward-looking statements," including with regard to Mylan being better positioned under Mauro's leadership to identify commercial opportunities and best practices across the various regions to bring even greater value to its customers around the world and to continue its efforts to provide 7 billion people access to high quality medicine; that Mylan's future has never been brighter; and about Mylan's exciting growth trajectory and its mission to set new standards in healthcare. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the effect of any changes in our customer and supplier relationships and customer purchasing patterns; other changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on our business; any regulatory, legal, or other impediments to our ability to bring our products to market; actions and decisions of healthcare and pharmaceutical regulators, and changes in healthcare and pharmaceutical laws and regulations, in the United States and abroad; our ability to protect our intellectual property and preserve intellectual property rights; other uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,400 generic and branded pharmaceuticals, including antiretroviral therapies on which nearly 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in approximately 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our nearly 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.


'/>"/>
SOURCE Mylan N.V.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2015
2. Mylan lägger bud på Meda
3. Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30
4. Mylan to Report Fourth Quarter and Full Year 2015 Financial Results on Feb. 10, 2016
5. Mylan CFO John Sheehan to Retire as of April 1, 2016
6. Mylan Announces Worldwide Collaboration with Momenta to Jointly Develop and Commercialize Six Biosimilar Products
7. Mylan to Present at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
8. Mylan to Present at the J.P. Morgan 34th Annual Healthcare Conference
9. Mylan Announces Pricing of Senior Notes
10. On World AIDS Day, Mylan Announces Plans to be the First to Market Newly-Recommended Antiretroviral Treatment for $99 Per Patient, Per Year
11. Mylan Completes Acquisition of Certain Businesses from Famy Care to Create a Leading Womens Healthcare Franchise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... struggle women face in her book, Miracle Baby: A Fertility Doctor’s Fight for ... board-certified OB-GYN and fertility specialist, Noorhasan writes to educate, encourage, advise and support ...
(Date:10/8/2019)... TORONTO (PRWEB) , ... October 08, 2019 , ... ... oral delivery of lipid formulations which includes both soft elastic capsules and liquid ... of these technologies can provide formulators with effective delivery platforms during early-phase development ...
(Date:10/8/2019)... ... October 08, 2019 , ... ChoiceSpine LLC, a privately-held spinal device ... the company’s expertise, deepen its knowledge base, and drive sales growth. , The following ... KC Gilbert promoted to Senior Vice President of Strategic Partnerships; ...
Breaking Medicine Technology:
(Date:10/15/2019)... ... 2019 , ... An October 3 article on CNN Health explains ... points out that both agents are mildly abrasive; so while they may be good ... toothpastes, they are also good at stripping the enamel off of teeth if used ...
(Date:10/15/2019)... ... October 15, 2019 , ... In 2019, Unitek opened its doors to various ... late 2018 . Students who started in July were only entering their second term ... students would have to start over. Then the leadership team at Unitek honored their ...
(Date:10/15/2019)... ... October 15, 2019 , ... Nashville Fertility Center (NFC) is proud to ... to join the practice. In addition to treating general infertility, Dr. Van Heertum offers ... at NFC looks forward to Dr. Van Heertum joining the practice and believes she ...
(Date:10/11/2019)... ... October 11, 2019 , ... Inland Detox, Inc. has just moved ... location has incredible views of the Temecula Valley and it’s the perfect place for ... facility offers both private rooms as well as double occupancy rooms, a 2nd home ...
(Date:10/10/2019)... ... , ... AltMed Florida , one of the fastest growing Medical Marijuana ... opening of its second MÜV™ Medical Cannabis Dispensary on the First Coast – scheduled ... Beach. , Located at Beach Plaza Shopping Center at the corner of Beach Boulevard ...
Breaking Medicine News(10 mins):